Literature DB >> 29333136

Highlight report: The relationship of DNA copy number alterations and mRNA levels in cancer.

Seddik Hammad1.   

Abstract

Entities:  

Year:  2017        PMID: 29333136      PMCID: PMC5763088          DOI: 10.17179/excli2017-1043

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.



Recently, a genome-wide study about gene copy number gains and corresponding expression levels has been analyzed in a cohort of 190 non-small cell lung cancer (NSCLC) patients (Jabs et al., 2017[5]). The authors report that approximately half of the analyzed gene copy number-gene expression pairs correlated significantly. However, only 1.6 % (corresponding to 301 genes) of the analyzed pairs (gene copy number- mRNA) showed very strong correlations with a correlation coefficient higher than 0.7 (Jabs et al., 2017[5]). The authors studied the location of these 301 genes and observed that they are found predominantly in 10 chromosomal `hotspot regions´ with a width of approximately 15 Mbp. The most probable explanation of these `hotspots´ is that these genes show higher mean expression levels; moreover, copy number variations are more likely in these regions. Both, mRNA expression level and the frequency of copy number gain in the patient cohort were significantly associated with the correlation coefficient of copy number-gene expression pairs. An interesting result is that some of the genes with high correlation between copy number and mRNA levels are significantly associated with survival. Indeed, prognostic genes were overrepresented among the subset of highly correlating copy number-gene expression pairs (Jabs et al., 2017[5]). Since decades, much effort has been invested to better understand the relationship between gene expression and prognosis of tumors (Hellwig et al., 2016[4]; Stock et al., 2015[13]; Sicking et al., 2014[12][11]; Ghallab et al., 2015[2]; Malik et al., 2015[9]; Lohr et al., 2015[8]; Shakeri et al., 2016[10]). However, it has also become clear that it is challenging to achieve a relevant improvement of prognostication by gene expression signatures compared to the use of clinicopathological parameters alone (Grinberg et al., 2017[3]; Sicking et al., 2014[12][11]). A further research focus is the identification of improved anti-cancer agents and the identification of subsets of patients who profit from a specific chemotherapy (Uzor, 2016[15]; Jigyasu et al., 2016[6]; Kwak et al., 2016[7]; Benarba, 2015[1]; Tatokoro et al., 2015[14]). It is often easier to isolate DNA from archived tumor material than obtaining the easily degradable mRNA. The systematic study of Jabs et al. identified a subset of genes with a very strong correlation of DNA copy number and mRNA levels. Therefore, further analysis of prognostic or predictive relevance of these genes can be performed based on DNA which may facilitate progress in this field of research.
  15 in total

1.  Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer.

Authors:  Anna-Maria Stock; Franziska Klee; Karolina Edlund; Marianna Grinberg; Seddik Hammad; Rosemarie Marchan; Cristina Cadenas; Bernd Niggemann; Kurt S Zänker; Jörg Rahnenführer; Marcus Schmidt; Jan G Hengstler; Frank Entschladen
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

2.  Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Authors:  Marianna Grinberg; Dijana Djureinovic; Hans Rr Brunnström; Johanna Sm Mattsson; Karolina Edlund; Jan G Hengstler; Linnea La Fleur; Simon Ekman; Hirsh Koyi; Eva Branden; Elisabeth Ståhle; Karin Jirström; Derek K Tracy; Fredrik Pontén; Johan Botling; Jörg Rahnenführer; Patrick Micke
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

3.  Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.

Authors:  Isabel Sicking; Karlien Rommens; Marco J Battista; Daniel Böhm; Susanne Gebhard; Antje Lebrecht; Cristina Cotarelo; Gerald Hoffmann; Jan G Hengstler; Marcus Schmidt
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

4.  Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.

Authors:  Isabel Sicking; Karolina Edlund; Eva Wesbuer; Veronika Weyer; Marco J Battista; Antje Lebrecht; Christine Solbach; Marianna Grinberg; Johannes Lotz; Gerald Hoffmann; Jörg Rahnenführer; Jan G Hengstler; Marcus Schmidt
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

5.  Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.

Authors:  Birte Hellwig; Katrin Madjar; Karolina Edlund; Rosemarie Marchan; Cristina Cadenas; Anne-Sophie Heimes; Katrin Almstedt; Antje Lebrecht; Isabel Sicking; Marco J Battista; Patrick Micke; Marcus Schmidt; Jan G Hengstler; Jörg Rahnenführer
Journal:  PLoS One       Date:  2016-12-07       Impact factor: 3.240

6.  Anti-cancer activities of Brassica juncea leaves in vitro.

Authors:  Youngeun Kwak; Jungjae Lee; Jihyeung Ju
Journal:  EXCLI J       Date:  2016-11-15       Impact factor: 4.068

7.  Highlight report: Role of the circadian clock system in breast cancer.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2015-04-14       Impact factor: 4.068

8.  Recent developments on potential new applications of emetine as anti-cancer agent.

Authors:  Philip F Uzor
Journal:  EXCLI J       Date:  2016-05-10       Impact factor: 4.068

9.  DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.

Authors:  Halaleh Shakeri; Jalal Gharesouran; Ashraf Fakhrjou; Ali Esfahani; Seyyed Mojtaba Mohaddes Ardebili
Journal:  EXCLI J       Date:  2016-01-11       Impact factor: 4.068

Review 10.  Heat shock protein 90 targeting therapy: state of the art and future perspective.

Authors:  Manabu Tatokoro; Fumitaka Koga; Soichiro Yoshida; Kazunori Kihara
Journal:  EXCLI J       Date:  2015-01-06       Impact factor: 4.068

View more
  1 in total

1.  3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset.

Authors:  Hugh Andrew Jinwook Kim; Mushfiq Hassan Shaikh; Mark Lee; Peter Y F Zeng; Alana Sorgini; Temitope Akintola; Xiaoxiao Deng; Laura Jarycki; Halema Khan; Danielle MacNeil; Mohammed Imran Khan; Adrian Mendez; John Yoo; Kevin Fung; Pencilla Lang; David A Palma; Krupal Patel; Joe S Mymryk; John W Barrett; Paul C Boutros; Luc G T Morris; Anthony C Nichols
Journal:  Cancers (Basel)       Date:  2021-10-22       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.